Lv4
760 积分 2023-04-11 加入
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
1个月前
已完结
Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma
1个月前
已完结
Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC
1个月前
已完结
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
1个月前
已完结
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
2个月前
已完结
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
2个月前
已完结
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
2个月前
已完结
Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL
2个月前
已完结
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients
2个月前
已完结
CNS prophylaxis for diffuse large B-cell lymphoma
2个月前
已完结
皖公网安备34019202002308
